Histologically confirmed metastatic malignant melanoma with an indication for immunotherapy (Nivolumab and Ipilimumab).
The participant provides written informed consent for the study.
The participant is at least 18 years of age on the day the informed consent is signed.
No prior systemic anticancer therapy for metastatic disease (e.g., cytotoxic or targeted agents).
ECOG (Eastern Cooperative Oncology Group) performance status score of ≤ 2.
No physical impairment that would preclude participation in physical exercise.
You may not be if
Major surgery within 2 weeks prior to the start of the study intervention, or participants who have not fully recovered from the effects of a previous surgery.
Participants with a diagnosed immunodeficiency, or those receiving chronic systemic corticosteroid therapy (at a dose greater than 10 mg prednisone equivalent per day), or any other form of immunosuppressive therapy within 7 days prior to the first dose of the study medication.
Participants with an active infection requiring systemic therapy.
Participants with a known history of infection with human immunodeficiency virus (HIV) or hepatitis.
Clareo Health | Physical Activity Directly Before Immunotherapy (Nivolumab and Ipilimumab) in Melanoma
